Skip to main content

CORRECTION article

Front. Oncol., 22 September 2022
Sec. Pharmacology of Anti-Cancer Drugs
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1007616

Corrigendum: Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity

This article is a correction to:

  1. Case Report: Initial Treatment Adjustments and Complications in Ovarian Cancer Patient With Inborn Error of Immunity

    1. Read original article
Jamila Mammadova*Jamila Mammadova1*Anna ReddenAnna Redden2Rachel CruzRachel Cruz1Boglarka UjhaziBoglarka Ujhazi3Sumai GordonSumai Gordon3Maryssa EllisonMaryssa Ellison3Tyra GatewoodTyra Gatewood4Carla DuffCarla Duff3Anthony CannellaAnthony Cannella5Charurut SomboonwitCharurut Somboonwit5Chakrapol SriaroonChakrapol Sriaroon5Krisztian CsomosKrisztian Csomos3Joseph F. DassoJoseph F. Dasso3Terry HarvilleTerry Harville6Roohi Ismail-KhanRoohi Ismail-Khan7Jolan E. WalterJolan E. Walter3
  • 1Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  • 2Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States
  • 3Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  • 4Department of Pharmacy at Gynecologic and Neuro Oncology Clinics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
  • 5Division of Infectious Disease and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States
  • 6Division of Hematology, Department of Pathology and Laboratory Services, and Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States
  • 7Department of Cardio-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

A corrigendum on
Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity

by Mammadova J, Redden A, Cruz R, Ujhazi B, Gordon S, Ellison M, Gatewood T, Duff C, Canella A, Somboonwit C, Sriaroon C, Csomos K, Dasso JF, Harville T, Ismail-Khan R and Walter JE (2022) Front. Oncol. 12:843741. doi: 10.3389/fonc.2022.843741

In the published article, there was an error in the author list, and authors Boglarka Ujhazi, Sumai Gordon, and Krisztian Csomos were erroneously excluded. In addition, their author contributions statement has been updated. The corrected statement reads as follows:

JM - manuscript write up, data collection, patient interview. AR - manuscript write up, literature review. RC - manuscript write up. ME - clinical research coordination. TG - pharmacy in gynecology clinic. CD, KC, BU, and SG - immunologic evaluation. AC - control of infectious diseases. CSo - control of infectious diseases. CSr - control of pulmonary infections. JD - manuscript write up, immunologic evaluation, literature review. TH - early treating immunologist, primary diagnosis with IEI. RI-K - treating oncologist. JW - currently treating immunologist, primary investigator. All authors contributed to the article and approved the submitted version.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: antibody deficiency, primary immunodeficiency, ovarian cancer, case report, inborn error of immunity

Citation: Mammadova J, Redden A, Cruz R, Ujhazi B, Gordon S, Ellison M, Gatewood T, Duff C, Cannella A, Somboonwit C, Sriaroon C, Csomos K, Dasso JF, Harville T, Ismail-Khan R and Walter JE (2022) Corrigendum: Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity. Front. Oncol. 12:1007616. doi: 10.3389/fonc.2022.1007616

Received: 30 July 2022; Accepted: 17 August 2022;
Published: 22 September 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Mammadova, Redden, Cruz, Ujhazi, Gordon, Ellison, Gatewood, Duff, Cannella, Somboonwit, Sriaroon, Csomos, Dasso, Harville, Ismail-Khan and Walter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jamila Mammadova, jmammadova@usf.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.